Novartis has obtained US Food and Drug Administration (FDA) marketing authorization for 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC). This new drug is marketed under the name of PluvictoTM and is associated with the diagnostic product, 68Ga-PSMA-11, under the name of Locametz®.
This first marketed radioligand therapy for prostate cancer is a promising news and building hope for prostate cancer patients and a significant event for the Radiotheranostics field.
This FDA authorization is based on the results of the Phase III VISION trial.